表纸
市场调查报告书

中枢神经系统的联盟的全球市场:交易趋势,企业,财务状况

Global Central Nervous System Partnering 2014-2020: Deal trends, players and financials

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品编码 250308
出版日期 内容资讯 英文 950+ Pages
商品交期: 最快1-2个工作天内
价格
中枢神经系统的联盟的全球市场:交易趋势,企业,财务状况 Global Central Nervous System Partnering 2014-2020: Deal trends, players and financials
出版日期: 2020年10月01日内容资讯: 英文 950+ Pages
简介

本报告提供1,500个以上的中枢神经系统 (CNS)的交易相关调查分析,以可利用的交易、合同为对象,交易趋势和详细资料相关的系统性资讯。

摘要整理

第1章 简介

第2章 中枢神经系统的交易的趋势

  • 简介
  • 多年的中枢神经系统的联盟
  • 中枢神经系统的联盟:各交易类型
  • 中枢神经系统的联盟:各产品部门
  • 中枢神经系统的联盟:各开发阶段
  • 中枢神经系统的联盟:各技术类型
  • 中枢神经系统的联盟:各治疗适应症

第3章 对中枢神经系统的联盟的金融交易条件

  • 简介
  • 对中枢神经系统的联盟的财务状况的揭露
  • 中枢神经系统的联盟的标题价值
  • 中枢神经系统的交易的预付款
  • 中枢神经系统的交易的目标达成赏金
  • 中枢神经系统的特许权费率

第4章 主要中枢神经系统的交易与交易业者

  • 简介
  • 中枢神经系统的联盟最活跃
  • 中枢神经系统最活跃的交易业者的清单
  • 主要的中枢神经系统的交易:各金额

第5章 中枢神经系统的合同名录

  • 简介
  • 可利用的合同的中枢神经系统的联盟交易

第6章 中枢神经系统的交易:各治疗标的

  • 简介
  • 交易:各治疗标的

附录

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: CP2203

The Global Central Nervous System Partnering 2014 to 2020: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the central nervous system (cns) partnering deals and agreements entered into by the worlds leading healthcare companies

Global Central Nervous System Partnering 2014 to 2020 provides the full collection of Central Nervous System disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.

Trends in Central Nervous System partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Central Nervous System partnering agreement structure

Central Nervous System partnering contract documents

Top Central Nervous System deals by value

Most active Central Nervous System dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Central Nervous System disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Central Nervous System deals.

The report presents financial deal terms values for Central Nervous System deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Central Nervous System dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Central Nervous System dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Central Nervous System deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Central Nervous System dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Central Nervous System deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Central Nervous System partnering deals by specific Central Nervous System target announced since 2014. The chapter is organized by specific Central Nervous System therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Central Nervous System partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Central Nervous System partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Central Nervous System technologies and products.

Report scope

Global Central Nervous System Partnering 2014 to 2020 is intended to provide the reader with an in-depth understanding and access to Central Nervous System trends and structure of deals entered into by leading companies worldwide.

Global Central Nervous System Partnering 2014 to 2020 includes:

  • Trends in Central Nervous System dealmaking in the biopharma industry since 2014
  • Analysis of Central Nervous System deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Central Nervous System deal contract documents
  • Comprehensive access to over 1,400 Central Nervous System deal records
  • The leading Central Nervous System deals by value since 2014
  • Most active Central Nervous System dealmakers since 2014
  • The report includes deals for the following indications: Cerebral palsy, Creutzfeldt Jakob disease, Dizziness, Epilepsy, Faints, Falls, Guillain Barre syndrome, Headache, Meningitis (Bacterial, Meningococcal, Pneumococcal), Mycobacterium tuberculosis (TB), Haemophilus influenzae Type B (Hib), Migraine, Motor Neurone Disease (Amyotrophic Lateral Sclerosis/Lou Gehrig's Disease, Multiple sclerosis, Nausea, Neuropathy, Pain, Neuralgia, Fibromyalgia, Paralysis, Parkinson's disease, Restless leg syndrome, Spinal cord, Stroke, Stuttering, Traumatic Brain Injury, Vertigo, Weakness, plus other CNS indications.

In Global Central Nervous System Partnering 2014 to 2020, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication
  • Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Central Nervous System Partnering 2014-2020 report provides comprehensive access to available deals and contract documents for over 1,400 central nervous system deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Central Nervous System Partnering 2014 to 2020 provides the reader with the following key benefits:

  • In-depth understanding of Central Nervous System deal trends since 2014
  • Access Central Nervous System deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Central Nervous System partner companies
  • Comprehensive access to over 1,400 links to actual Central Nervous System deals entered into by the world's biopharma companies
  • Indepth review of Central Nervous System deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Central Nervous System opportunities
  • Uncover companies actively partnering Central Nervous System opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Central Nervous System dealmaking

  • 2.1. Introduction
  • 2.2. Central Nervous System partnering over the years
  • 2.3. Central Nervous System partnering by deal type
  • 2.4. Central Nervous System partnering by industry sector
  • 2.5. Central Nervous System partnering by stage of development
  • 2.6. Central Nervous System partnering by technology type
  • 2.7. Central Nervous System partnering by therapeutic indication

Chapter 3 -Financial deal terms for Central Nervous System partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for Central Nervous System partnering
  • 3.3. Central Nervous System partnering headline values
  • 3.4. Central Nervous System deal upfront payments
  • 3.5. Central Nervous System deal milestone payments
  • 3.6. Central Nervous System royalty rates

Chapter 4 - Leading Central Nervous System deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in Central Nervous System partnering
  • 4.3. List of most active dealmakers in Central Nervous System
  • 4.4. Top Central Nervous System deals by value

Chapter 5 - Central Nervous System contract document directory

  • 5.1. Introduction
  • 5.2. Central Nervous System partnering deals where contract document available

Chapter 6 - Central Nervous System dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by Central Nervous System therapeutic target

Appendices

  • Appendix 1 - Directory of Central Nervous System deals by company A-Z 2014 to 2020
  • Appendix 2 - Directory of Central Nervous System deals by deal type 2014 to 2020
  • Appendix 3 - Directory of Central Nervous System deals by stage of development 2014 to 2020
  • Appendix 4 - Directory of Central Nervous System deals by technology type 2014 to 2020
  • Further reading on dealmaking
  • Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering
  • Table of figures
  • Figure 1: Central Nervous System partnering since 2014
  • Figure 2: Central Nervous System partnering by deal type since 2014
  • Figure 3: Central Nervous System partnering by industry sector since 2014
  • Figure 4: Central Nervous System partnering by stage of development since 2014
  • Figure 5: Central Nervous System partnering by technology type since 2014
  • Figure 6: Central Nervous System partnering by indication since 2014
  • Figure 7: Central Nervous System deals with a headline value
  • Figure 8: Central Nervous System deals with upfront payment values
  • Figure 9: Central Nervous System deals with milestone payment
  • Figure 10: Central Nervous System deals with royalty rates
  • Figure 11: Active Central Nervous System dealmaking activity- 2014 to 2020
  • Figure 12: Top Central Nervous System deals by value since 2014